NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASADAQGS:SLDB) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/SLDB-Info-Request-Form-1868. There is no cost or obligation to you.
On March 14, 2018, Solid Biosciences issued a press release announcing receipt of a “notification from the U.S. Food and Drug Administration that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.” Upon this news, shares of Solid Biosciences fell from a close of $26.31 on March 14, 2018 to a close of $9.32 on March 15, 2018.
To learn more about the investigation of Solid Biosciences contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SLDB-Info-Request-Form-1868.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.